Grant List
Represents Grant table in the DB
GET /v1/grants?page%5Bnumber%5D=1392&sort=funder
{ "links": { "first": "https://cic-apps.datascience.columbia.edu/v1/grants?page%5Bnumber%5D=1&sort=funder", "last": "https://cic-apps.datascience.columbia.edu/v1/grants?page%5Bnumber%5D=1392&sort=funder", "next": null, "prev": "https://cic-apps.datascience.columbia.edu/v1/grants?page%5Bnumber%5D=1391&sort=funder" }, "data": [ { "type": "Grant", "id": "12226", "attributes": { "award_id": "1R44AI179348-01", "title": "Opaganib as a Medical Countermeasure for Gastrointestinal Acute Radiation Syndrome", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Institute of Allergy and Infectious Diseases (NIAID)" ], "program_reference_codes": [], "program_officials": [ { "id": 28095, "first_name": "Merriline M.", "last_name": "Vedamony", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2023-08-01", "end_date": "2025-07-31", "award_amount": 852174, "principal_investigator": { "id": 28096, "first_name": "Charles D", "last_name": "Smith", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [], "awardee_organization": { "id": 2078, "ror": "", "name": "APOGEE BIOTECHNOLOGY CORPORATION", "address": "", "city": "", "state": "PA", "zip": "", "country": "United States", "approved": true }, "abstract": "The Radiation Countermeasures Program of the NIAID is seeking medical countermeasures (MCMs) to prevent acute tissue damage and chronic pathologies resulting from exposure to ionizing radiation from an accidental or terroristic event. Radiation induces inflammatory cytokines that promote tissue damage including Gastrointestinal Acute Radiation Syndrome (GI-ARS). Because there are no approved drugs to prevent GI-ARS, there is an intense need for new drugs for therapy following exposure to radiation. Sphingolipids, particularly ceramides and sphingosine 1-phosphate (S1P), regulate GI epithelial cell survival, the DNA damage response, and responses to inflammatory cytokines. Synthesis of S1P is dependent on sphingosine kinase (SK1 and SK2) activity, and so SKs are rational new molecular targets to mitigate GI-ARS. Apogee has developed the first-in- class Investigational New Drug opaganib (previously called ABC294640). Opaganib is the only clinical-stage inhibitor of SK2 and has broad anticancer and anti-inflammatory efficacy in preclinical models. Phase 1 clinical trials of orally-administered opaganib to patients with advanced solid tumors or multiple myeloma are complete, and Phase 2 clinical trials of opaganib in patients with prostate cancer or cholangiocarcinoma are in progress. Additionally, opaganib improved clinical outcome for highly compromised patients with severe Covid-19. To date, opaganib has been administered to >470 patients with a favorable safety profile. Because GI-ARS is mediated by epithelial cell apoptosis and excessive inflammation, processes regulated by sphingolipids, we hypothesized that opaganib will decrease GI damage from radiation exposure leading to mitigation of GI-ARS and improved survival. In Proof-of-Concept studies supported by the Biomedical Advanced Research and Development Authority and the Department of Defense, we demonstrated that oral opaganib provides highly significant protection against mortality from GI-ARS in mice following irradiation in a 5% bone marrow-shielded model. Opaganib increased survival when administered either prior to radiation or 24 hr after radiation exposure and was efficacious at levels that have been demonstrate safe in human trials. In a pre-IND meeting, the FDA encouraged the continue development of opaganib as an MCM for GI-ARS under the Animal Rule for regulatory approval. Specific requirements for approval were identified, and are addressed in the following Specific Aims for this Phase 2 SBIR project: 1. Definition of the biochemical mechanism(s) for protection against radiation-induced cell death and inflammation in intestinal epithelial cells; 2. Definition of the effect of radiation exposure on the pharmacokinetics (PKs) of orally-administered opaganib; and 3. Identification of assessable pharmacodynamic (PD) biomarkers for opaganib for future pivotal animal studies and human clinical trials. The studies proposed herein follow FDA guidance for approval under the Animal Rule and will enable continued advancement of opaganib as an MCM for GI-ARS.", "keywords": [ "Accidents", "Acute", "Address", "Affect", "Animal Model", "Animals", "Anti-Inflammatory Agents", "Apoptosis", "Authorization documentation", "Autophagocytosis", "Biochemical", "Biological Availability", "Biological Markers", "Bone Marrow", "Cell Cycle Arrest", "Cell Death Induction", "Cell Survival", "Cell physiology", "Ceramides", "Cholangiocarcinoma", "Chronic", "Clinical", "Clinical Trials", "DNA Damage", "DNA Repair", "DNA lesion", "Department of Defense", "Development", "Dose", "Down-Regulation", "Drug Kinetics", "Epithelial Cells", "Event", "Exposure to", "Future", "Generations", "Goals", "Human", "Induction of Apoptosis", "Inflammation", "Inflammatory", "Interleukin-6", "Investigational Drugs", "Ionizing radiation", "Malignant neoplasm of prostate", "Mediating", "Methods", "Modeling", "Molecular Target", "Multiple Myeloma", "Mus", "NF-kappa B", "National Institute of Allergy and Infectious Disease", "Oral", "Oral Administration", "Outcome", "Pathology", "Patients", "Persons", "Pharmaceutical Preparations", "Pharmacotherapy", "Phase", "Phase I Clinical Trials", "Phase II Clinical Trials", "Plasma", "Pre-Clinical Model", "Process", "Production", "Proteins", "Qualifying", "Radiation", "Radiation Accidents", "Radiation Dose Unit", "Radiation Induced DNA Damage", "Radiation Protection", "Radiation Toxicity", "Radiation exposure", "Radiation induced damage", "Role", "Safety", "Sampling", "Signal Pathway", "Small Business Innovation Research Grant", "Solid Neoplasm", "Sphingolipids", "TNF gene", "Testing", "Tissues", "Toxicology", "animal rule", "anti-cancer", "authority", "c-myc Genes", "cell killing", "chemical stability", "cytokine", "drug development", "efficacy study", "gastrointestinal", "improved", "in vitro activity", "in vivo", "inhibitor", "intestinal epithelium", "irradiation", "liquid chromatography mass spectrometry", "medical countermeasure", "mortality", "novel therapeutics", "pharmacodynamic biomarker", "pharmacologic", "pre-Investigational New Drug meeting", "prevent", "programs", "radiation countermeasure", "radiation effect", "radioprotected", "repaired", "research and development", "response", "severe COVID-19", "sphingosine 1-phosphate", "sphingosine kinase" ], "approved": true } }, { "type": "Grant", "id": "12227", "attributes": { "award_id": "1RF1MH134638-01", "title": "International evaluation of modifiable social determinants of health on COVID-related mental health outcomes", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Institute of Mental Health (NIMH)" ], "program_reference_codes": [], "program_officials": [ { "id": 25615, "first_name": "Leonardo", "last_name": "Cubillos", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2023-08-02", "end_date": "2026-07-31", "award_amount": 3155102, "principal_investigator": { "id": 28097, "first_name": "Sarah Diana", "last_name": "Bauermeister", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [ { "id": 22910, "first_name": "JORDAN W", "last_name": "SMOLLER", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, { "id": 28098, "first_name": "André Russowsky", "last_name": "Brunoni", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "awardee_organization": { "id": 736, "ror": "https://ror.org/002pd6e78", "name": "Massachusetts General Hospital", "address": "", "city": "", "state": "MA", "zip": "", "country": "United States", "approved": true }, "abstract": "A substantial body of research suggests that the COVID-19 pandemic has contributed to a rising incidence of mental health issues, irrespective of prior history of psychiatric diagnosis. One important driver of this phenomenon appears to be social isolation and loneliness induced by governmental policy responses such as social distancing recommendations, stay-at-home orders, and restrictions on travel. However, results thus far have been mixed across cohorts and geographic regions, and the social and individual factors underlying these differences remain poorly understood. Moreover, existing efforts have largely focused on high-income countries (HIC), which may not generalize to understudied low- and middle-income countries (LMIC), regions most impacted by the pandemic and where 85% of the world population lives. A key opportunity for mitigating future mental health impacts and increasing representation of marginalized groups in COVID-19 mental health research is to leverage individual-level longitudinal data harmonized across existing cohorts to develop a well-powered, large, global evaluation of pandemic-related mental health outcomes. Our proposal capitalizes on existing large international cohorts, establishing a COVID Global Mental Health Consortium (CGMHC) to increase our understanding of the modifiable social and individual risk factors predicting poor mental health in response to the pandemic, and to build an infrastructure to answer broader questions about the local and global determinants of COVID-19 related psychiatric outcomes, ultimately informing public policy, intervention, and prevention strategies. To accomplish this, we will integrate: (1) data from 23 international cohorts comprising mental health, sociodemographic, and social determinants of health (SDoH) from nearly 2.8 million individuals with pre- and post-pandemic assessments; (2) a novel target trial emulation framework to facilitate causal inference about the impact of specific pandemic policy strategies on mental health outcomes; and (3) recent advances in time-series modeling and novel risk prediction methods to understand the heterogeneity of mental health outcomes in response to social restrictions across a diverse range of countries. Our specific aims are to: (1) assemble longitudinal data across global cohorts, harmonizing data for downstream analyses and develop a data visualization platform for the scientific community; (2) characterize pandemic mental health trajectories along with their moderators and evaluate the evidence for a causal impact of social containment policies on psychiatric outcomes. (3) establish and formalize the CGMHC for continued research on the impact of the COVID-19 pandemic on global mental health and SDoH. Successful completion of these aims would provide a unique large-scale global cohort resource for the investigation of COVID-related mental health outcomes, inform intervention and policy strategies to mitigate future adverse impacts, and create an ongoing engine (the CGMHC) for collaborative research that can be sustained through future funding.", "keywords": [ "Address", "Anxiety", "Attention", "COVID-19", "COVID-19 pandemic", "COVID-19 pandemic effects", "Cohort Analysis", "Communities", "Containment", "Country", "Data", "Data Set", "Dementia", "Directories", "Evaluation", "Funding", "Future", "Geographic Locations", "Health", "Heterogeneity", "Impaired cognition", "Incidence", "Income", "Individual", "Infrastructure", "International", "Interruption", "Intervention", "Investigation", "Joints", "Knowledge", "Loneliness", "Measures", "Mental Depression", "Mental Health", "Mental disorders", "Methods", "Modeling", "National Institute of Mental Health", "Ontology", "Outcome", "Participant", "Policies", "Population", "Predictive Factor", "Prevention strategy", "Psychiatric Diagnosis", "Psychological Factors", "Public Health", "Public Policy", "Recommendation", "Recording of previous events", "Research", "Research Personnel", "Research Project Grants", "Resources", "Risk", "Risk Factors", "Role", "Series", "Social Distance", "Social isolation", "Time", "Time trend", "Travel", "Unemployment", "Variant", "Visualization software", "cohort", "coronavirus disease", "data harmonization", "data resource", "data standards", "data visualization", "experience", "global health", "health care availability", "health data", "health disparity", "low and middle-income countries", "marginalized population", "mortality", "novel", "pandemic disease", "pandemic impact", "post-pandemic", "pre-pandemic", "psychiatric symptom", "randomized trial", "resilience", "resilience factor", "response", "risk prediction", "social", "social factors", "social health determinants", "social influence", "sociodemographics", "stay-at-home order", "substance use", "suicidal", "tool", "trend", "working group" ], "approved": true } }, { "type": "Grant", "id": "12228", "attributes": { "award_id": "1R01NR020601-01A1", "title": "Health Disparities in Hospice in Nursing Homes", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Institute of Nursing Research (NINR)" ], "program_reference_codes": [], "program_officials": [ { "id": 6036, "first_name": "Karen", "last_name": "Kehl", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2023-08-23", "end_date": "2027-06-30", "award_amount": 716574, "principal_investigator": { "id": 28099, "first_name": "Lara K", "last_name": "Dhingra", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [ { "id": 20721, "first_name": "Patricia W.", "last_name": "Stone", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, { "id": 28100, "first_name": "Andrew Wylie", "last_name": "Dick", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "awardee_organization": { "id": 781, "ror": "", "name": "COLUMBIA UNIVERSITY HEALTH SCIENCES", "address": "", "city": "", "state": "NY", "zip": "", "country": "United States", "approved": true }, "abstract": "In the US, more than 15,600 nursing homes (NHs) provide long-term care to more than 1.3 million elderly adults, of whom about 20% are racial and ethnic minorities. About 40% of NH residents have advanced illness, and prior to the pandemic more than 27% of all deaths in those ages 65 years or older occurred in NHs, making high-quality end-of-life (EOL) care critical. Prior research has found racial and ethnic disparities in NH EOL care. Hospice, a government benefit, allows for EOL care to be provided by a specialist interdisciplinary team. Timely hospice enrollment is a best practice and is recommended for NH residents with advanced illness. However, of those dying in NHs only 1/3 enroll in hospice, and 30% of the enrolled residents receive hospice care for less than a week. Concerns about disparities in NHs related to implicit bias, systemic racism, and structural racism increased with the pandemic. During 2020, racial and ethnic minority NH residents were disproportionately affected by COVID-19 as mortality rose by 32%, yet hospice use decreased in most states. There are gaps in knowledge about racial and ethnic disparities in NH hospice enrollment, the quality of hospice care provided, and related EOL outcomes. How the pandemic impacted hospice use and if any related changes were long lasting is also unknown. To address these gaps, we propose a sequential explanatory mixed methods study guided by Donabedian's Structure, Process, and Outcomes Quality Framework and the NIMHD Minority Health and Health Disparities Framework. Our aims are to: 1) Identify racial and ethnic differences in hospice enrollment and the quality of hospice care provided over time, factors that influence these differences, and how COVID-19 changed these differences; 2) Identify racial and ethnic differences in NH EOL outcomes over time, factors that influence these differences including hospice enrollment and the quality of hospice care, and how COVID-19 changed these differences; and 3) Describe perceived facilitators and barriers that contribute to hospice use and quality of hospice care in racial and ethnic minority NH residents. To achieve Aims 1 and 2, we will use administrative and publicly available data from 2015 to 2024, including the Minimum Data Set and Medicare hospice and inpatient claims (n ≈ 8 million) of NH residents who died and a subset of this sample who enrolled in hospice (n ≈ 2 million). We will include all available racial and ethnic categories and comprehensive measures of hospice enrollment, hospice quality of care, and EOL outcomes. To meet Aim 3, we will purposively sample 16 NHs that vary in location, are either high or low users of hospice, and ≥ 30% of residents are racial or ethnic minorities. We will conduct semi-structured interviews with an administrator, hospice care planner, and 2 family caregivers of racial/ethnic minority decedents (i.e., one that used hospice and one that did not) from each NH. Results from this study will inform evidence-based policies at the national, state, and NH level and influence practice-based initiatives that can promote equitable access to high-quality hospice for diverse Americans living and dying in NHs.", "keywords": [ "Address", "Administrator", "Adult", "Age", "Alaska Native", "American", "American Indians", "Asian", "Biological", "Black race", "COVID-19", "COVID-19 impact", "COVID-19 pandemic", "Caring", "Categories", "Cessation of life", "Country", "Critical Care", "Data", "Data Set", "Delirium", "Disparity", "Elderly", "Emergency department visit", "Enrollment", "Equity", "Ethnic Origin", "Family", "Family Caregiver", "Government", "Health", "Hispanic", "Hospice Care", "Hospitalization", "Inequity", "Inpatients", "Institutional Racism", "Interview", "Knowledge", "Life", "Life Expectancy", "Location", "Long-Term Care", "Measures", "Medicare", "Methods", "Modeling", "National Institute on Minority Health and Health Disparities", "Native Hawaiian or Other Pacific Islander", "Not Hispanic or Latino", "Nursing Homes", "Outcome", "Pain", "Patients", "Policies", "Process", "Professional Education", "Quality Indicator", "Quality of Care", "Quality of life", "Race", "Recommendation", "Research", "Sampling", "Services", "Specialist", "Structural Racism", "Structure", "Symptoms", "Time", "Visit", "Visiting Nurse", "advanced disease", "burden of illness", "decubitus ulcer", "disparity reduction", "end of life", "end of life care", "ethnic difference", "ethnic disparity", "ethnic minority", "evidence base", "health disparity", "hospice environment", "human old age (65+)", "implicit bias", "improved", "insight", "minority health", "minority health disparity", "mortality", "nursing skill", "outcome disparities", "pandemic disease", "pandemic impact", "programs", "racial difference", "racial disparity", "racial minority", "sex" ], "approved": true } }, { "type": "Grant", "id": "12229", "attributes": { "award_id": "1R01HL170961-01A1", "title": "Uncover mechanisms underlying the development of chronic lung sequelae post COVID-19", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Heart Lung and Blood Institute (NHLBI)" ], "program_reference_codes": [], "program_officials": [ { "id": 22589, "first_name": "CHRISTIAN RENE", "last_name": "Gomez", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2023-08-01", "end_date": "2027-07-31", "award_amount": 720284, "principal_investigator": { "id": 20818, "first_name": "Jie", "last_name": "Sun", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [ { "id": 1426, "ror": "", "name": "MAYO CLINIC ROCHESTER", "address": "", "city": "", "state": "MN", "zip": "", "country": "United States", "approved": true } ] }, "other_investigators": [ { "id": 28101, "first_name": "ROBERT", "last_name": "VASSALLO", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "awardee_organization": { "id": 908, "ror": "https://ror.org/0153tk833", "name": "University of Virginia", "address": "", "city": "", "state": "VA", "zip": "", "country": "United States", "approved": true }, "abstract": "Apart from the acute illness caused by SARS-CoV-2, it is now clear that a significant percentage of patients develop long-term conditions post COVID-19, including systemic and respiratory symptoms. Given the catastrophic spread of SARS-CoV-2 infection globally, there are many individuals that recover from acute COVID-19 and develop permanent impairment in lung function which can cause exertional dyspnea, fatigue (due to chronic hypoxia), and other limitations. This number will become even larger as the pandemic continues to progress. Therefore, there is an urgent need to understand the mechanisms underlying the development of chronic respiratory sequelae of COVID-19 to develop preventive and therapeutic interventions. In this application, we aim to unravel the driving mechanisms and identify potential therapeutic targets of chronic lung sequelae following COVID-19. To achieve this goal, we propose two Specific Aims (SA) for the study. SA 1. Decipher cellular and molecular traits underlying chronic lung sequelae post-acute COVID-19. We will enroll a group of COVID-19 convalescents that are expected to develop chronic lung sequelae after prior severe acute disease and a control population that completely recovered from previous mild or non-symptomatic COVID-19 infection. We will conduct comprehensive clinical examination supplemented by quantitative chest CT imaging and pulmonary function testing to determine clinical and pathophysiological characteristics of the two populations. We will collect longitudinal blood and bronchoalveolar lavage fluid (BAL) to obtain immune, molecular, and viral profiles in COVID-19 convalescents and controls. This unique approach integrating systemic and respiratory clinical, pathophysiological, cellular, molecular, and viral profiles of control or COVID- 19 convalescents will be highly compelling for future druggable target discovery. SA2. Model and validate targets of chronic lung sequelae post-acute COVID-19 in an animal model. We will establish a mouse model of chronic lung sequelae post-acute COVID-19. We will characterize systemic and respiratory host cellular and molecular responses in the model. integrate mouse and human data for validation of mechanistic links and discovery of new insights and/or targets for therapeutic interventions. We will then use the model to test whether target dysregulated respiratory CD8+ T cell responses could ameliorate chronic lung sequelae post-acute COVID-19. We will employ system biology tools to The successful completion of the study will generate unprecedented insights on clinical, viral, and immune traits of pulmonary sequelae, and will identify key causal immune mechanisms and therapeutic targets against chronic lung diseases post-acute COVID-19.", "keywords": [ "2019-nCoV", "Acute", "Acute Disease", "Address", "Adult", "Age Years", "Animal Model", "Automobile Driving", "Blood", "Bronchoalveolar Lavage Fluid", "CD8-Positive T-Lymphocytes", "CD8B1 gene", "COVID-19", "Characteristics", "Chronic", "Chronic Lung Injury", "Chronic lung disease", "Clinical", "Clinical Research", "Development", "Dyspnea", "Enrollment", "Exertion", "Exhibits", "Fatigue", "Fibrosis", "Future", "Goals", "Hospitalization", "Human", "Human Characteristics", "Hypoxia", "Immune", "Immune response", "Immunology", "Impairment", "Individual", "Infection", "Intervention", "Link", "Long COVID", "Longitudinal cohort", "Lung", "Lung immune response", "Memory", "Modeling", "Molecular", "Morbidity - disease rate", "Mus", "Pathologic", "Patients", "Physiological", "Population", "Population Control", "Post-Acute Sequelae of SARS-CoV-2 Infection", "Pulmonary function tests", "Resolution", "Respiratory Signs and Symptoms", "Role", "SARS-CoV-2 infection", "Sample Size", "Science", "Shortness of Breath", "Study models", "Survivors", "System", "Systems Biology", "T cell response", "T-Lymphocyte Subsets", "Testing", "Therapeutic Intervention", "Time", "Tissues", "Validation", "Viral", "Viral reservoir", "X-Ray Computed Tomography", "aged", "chest computed tomography", "clinical examination", "cohort", "data integration", "druggable target", "follow-up", "high risk", "human data", "insight", "long-term sequelae", "mortality", "mouse model", "new therapeutic target", "pandemic disease", "pathogen", "post-COVID-19", "predictive marker", "preventive intervention", "pulmonary function", "respiratory", "response", "targeted treatment", "therapeutic target", "tissue resident memory T cell", "tool", "trait" ], "approved": true } }, { "type": "Grant", "id": "12230", "attributes": { "award_id": "1R21AI173757-01A1", "title": "Vaccine-Induced Mucosal T-Cell Immunity to Respiratory Viruses in Dirty Mice", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Institute of Allergy and Infectious Diseases (NIAID)" ], "program_reference_codes": [], "program_officials": [ { "id": 7389, "first_name": "Halonna R.", "last_name": "Kelly", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2023-08-14", "end_date": "2025-07-31", "award_amount": 233250, "principal_investigator": { "id": 28102, "first_name": "Marulasiddappa", "last_name": "Suresh", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [], "awardee_organization": { "id": 799, "ror": "", "name": "UNIVERSITY OF WISCONSIN-MADISON", "address": "", "city": "", "state": "WI", "zip": "", "country": "United States", "approved": true }, "abstract": "Abstract: Respiratory infections have been among the top three leading causes of global deaths for decades. Their importance is reinforced by the emergence of novel highly transmissible respiratory pathogens, as witnessed in the current SARS-CoV-2 and past influenza pandemics. Current influenza and SARS-CoV-2 vaccines are focused on eliciting antibodies to highly mutable viral surface proteins, and frequent vaccine reformulations are needed to match the antigenicity of constantly evolving viral strains or variants that evade vaccine-elicited antibodies. Therefore, elicitation of lung tissue- resident memory T cells (TRMs), which recognize epitopes that are conserved across viral variants is critical to elicit broad anti-viral immunity. We have developed combination adjuvant-based subunit mucosal vaccine formulations that elicit exceptionally strong and functionally diverse lung/airway CD8 and CD4 TRMs and provide effective and broad protection against influenza A virus (IAV) and SARS-CoV-2 in specific-pathogen-free (SPF) mice. However, a central question is whether vaccine efficacy studies in SPF mice are translatable to humans, who are exposed to diverse microbial species. In recent years, Dirty mice (SPF mice cohoused with pet store mice), have been used to model human immune responses. Significantly, TRM numbers are greatly increased in Dirty mice, but the underlying mechanisms are unknown. We have exciting preliminary data that the lungs and spleen of Dirty mice have markedly elevated number of Granzyme BHI/CD44HI CD8 T cells with transcriptional attributes (T-betLO/EOMESLO/TCF-1LO) reminiscent of precursor TRMs, which are poised for a TRM cell fate. The overarching goal is to exploit the high resolution of our combination adjuvant-based vaccine approach and the Dirty mouse model to elucidate the effects of diverse microbial exposure on the development of pre-TRMs and their subsequent differentiation into TRMs that protect against respiratory viruses. Specific Aim 1 will test the hypothesis that diverse microbial exposure influences the development and protective functions of lung TRMs against IAV and SARS-CoV-2. Here, we will compare the development and transcriptional programming of lung TRMs induced by two combination adjuvant vaccine formulations and protective immunity to IAV and SARS-CoV-2 in SPF and Dirty mice. Specific Aim 2 will test the hypothesis that diverse microbial exposure promotes the conditioning of circulating/lymphoid pre-TRMs, leading to enhanced differentiation of TRMs in lungs of vaccinated Dirty mice. Here, in Dirty and SPF mice, we will incisively dissect whether diverse microbial exposure enhances the pre-conditioning of naïve CD8 or CD4 T cells prior to vaccination and/or antigen-activated effector T cells during vaccination, to a TRM cell fate. Impact:. Proposed studies will leverage microbial exposure to improve the rigor of mouse models to predict human immune response to vaccines, and provide mechanistic insights into the development of TRMs in the lung under conditions of diverse microbial exposure. Hence, this exploratory ‘high pay off’ R21 application blends significance and innovation to lay the conceptual framework for further mechanistic investigations that will pave the way for the development of a biologically relevant and translatable pre-clinical animal model to learn how we can leverage microbiota to enhance vaccine- induced T-cell immunity to IAV and SARS-CoV-2, which are human respiratory viruses of public health importance.", "keywords": [ "2019-nCoV", "Adjuvant", "Agonist", "Animal Model", "Antibodies", "Antigens", "Biomedical Research", "CD4 Positive T Lymphocytes", "CD8-Positive T-Lymphocytes", "CD8B1 gene", "COVID-19 vaccine", "Cell Count", "Cells", "Cessation of life", "Communicable Diseases", "Cytoprotection", "Data", "Development", "Epithelium", "Epitopes", "Exposure to", "Formulation", "Genetic", "Genetic Transcription", "Goals", "Granzyme", "Growth", "Hemagglutinin", "Human", "Immune response", "Immunity", "Immunologics", "Inbred Mouse", "Inbreeding", "Infection", "Influenza", "Influenza A virus", "Intranasal Administration", "Investigation", "Learning", "Link", "Lipid A", "Lung", "Lymphoid", "Membrane Proteins", "Memory", "Microbe", "Molecular", "Mucous Membrane", "Mus", "Mutation", "Neuraminidase", "Nucleoproteins", "Proteins", "Public Health", "Research", "Resolution", "Respiratory System", "Respiratory Tract Infections", "Seasons", "Seminal", "Site", "Spleen", "Structure of parenchyma of lung", "Subunit Vaccines", "Surface", "T cell response", "T-Lymphocyte", "TLR4 gene", "Testing", "Time", "Tissue Differentiation", "Tissues", "Translating", "Vaccinated", "Vaccination", "Vaccine Research", "Vaccines", "Variant", "Viral", "Viral Respiratory Tract Infection", "Virus Diseases", "Work", "antiviral immunity", "clinical practice", "conditioning", "effector T cell", "efficacy study", "experience", "germ free condition", "human model", "human pathogen", "immune system function", "improved", "influenza A virus nucleoprotein", "influenza virus strain", "influenza virus vaccine", "influenzavirus", "innovation", "insight", "interest", "microbial", "microbial community", "microbiome composition", "microbiota", "mouse model", "mucosal vaccine", "nanoemulsion", "novel", "pandemic influenza", "pre-clinical", "preconditioning", "protective efficacy", "pulmonary function", "respiratory pathogen", "respiratory virus", "response", "tissue resident memory T cell", "vaccine development", "vaccine efficacy", "vaccine formulation" ], "approved": true } }, { "type": "Grant", "id": "12231", "attributes": { "award_id": "1R01HD112362-01", "title": "Leveraging Telehealth to Identify Infants at Elevated Likelihood for Autism in the First Year of life", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)" ], "program_reference_codes": [], "program_officials": [ { "id": 9289, "first_name": "Alice S", "last_name": "Kau", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2023-08-15", "end_date": "2028-05-31", "award_amount": 643070, "principal_investigator": { "id": 28103, "first_name": "Meagan Ruth", "last_name": "Talbott", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [], "awardee_organization": { "id": 746, "ror": "", "name": "UNIVERSITY OF CALIFORNIA AT DAVIS", "address": "", "city": "", "state": "CA", "zip": "", "country": "United States", "approved": true }, "abstract": "Despite many decades of research in early identification of autism, there remain lengthy gaps between parents’ first concerns and formal diagnosis and subsequent access to specialized services. Challenges in reducing this gap include long waitlists, lack of specialized providers in many communities, and the lack of validated screening tools for infants under 18 months of age. Due to methodological challenges in recruiting sufficient numbers of infants with early specific concern for autism in any one geographic area, most studies of early development have focused on infant siblings of children with autism. Telehealth offers the opportunity to expand the scope of early identification studies and conduct the crucial foundational work needed to determine the developmental trajectories and outcomes of infants with early developmental concerns in community settings throughout the United States. We have previously demonstrated the initial feasibility of this approach in our preliminary work developing the Telehealth Evaluation of Development for Infants (TEDI; R21 HD100372 and R21 HD 105161, PI Talbott). Behavioral measures obtained via TEDI are reliable, valid, and highly satisfactory to families. Importantly, we have also found that the majority of infants in our sample have elevated scores on early measures of autism traits, developmental challenges in communication, language, and motor skills, and elevated likelihood of autism relative to general population norms. This preliminary work indicates the need for more thorough examination of this group of infants. We propose to prospectively follow a group of 100 infants ages 6 – 12 months with early parent concerns. We will evaluate them using the TEDI telehealth protocol at four visits each 3 months apart. At 36 months, we will conduct an outcome visit via telehealth to generate clinical best estimate outcomes. The project will address 3 specific aims. In Aim 1, we will determine the proportion and predictors of autism outcomes. Under Aim 2, we seek to characterize the development of a community-based sample of infants later diagnosed with autism by examining differences in developmental trajectories between outcome groups, as well as predictors of developmental outcomes across groups. Finally, in Aim 3, we will identify best practices for supporting family engagement and satisfaction with telehealth-based assessments, and the cultural appropriateness of the TEDI for diverse communities, which will directly support the implementation of telehealth screening and assessment in community settings beyond the COVID-19 pandemic. Successful completion of these aims has the potential to significantly increase families’ access to specialized evaluations and increase the capacity for early identification of infants in need of services. It will also lay the groundwork for future efforts to conduct screening and intervention trials and may ultimately help to increase access to high-quality interventions and improve the developmental outcomes of many more underserved children with autism and other NDD’s.", "keywords": [ "4 year old", "Address", "Age", "Age Months", "Attention deficit hyperactivity disorder", "COVID-19 pandemic", "Caregivers", "Child", "Clinical", "Clinical Research", "Communication", "Communities", "Data", "Development", "Developmental Course", "Developmental Process", "Devices", "Diagnosis", "Diagnostic", "Early Intervention", "Early identification", "Ensure", "Equity", "Evaluation", "Family", "Feedback", "Future", "General Population", "Geographic Locations", "Geography", "Goals", "Health Services Accessibility", "Healthcare", "Infant", "Infant Development", "Infant Health", "Intervention", "Intervention Studies", "Intervention Trial", "Language", "Life", "Measures", "Mediating", "Methodology", "Monitor", "Motor Skills", "Neurodevelopmental Disorder", "Outcome", "Parents", "Participant", "Play", "Protocols documentation", "Provider", "Psychosocial Factor", "Race", "Reporting", "Research", "Resource-limited setting", "Rural", "Sampling", "Screening procedure", "Services", "Siblings", "Social support", "Speech Delay", "Strategic Planning", "Stress", "Testing", "United States", "United States National Institutes of Health", "Visit", "Waiting Lists", "Work", "acceptability and feasibility", "autism spectrum disorder", "autistic children", "behavior measurement", "caregiver education", "community setting", "digital assessment", "digital health", "family support", "feasibility testing", "health assessment", "health care availability", "improved", "infancy", "infant outcome", "outreach", "personalized strategies", "prospective", "recruit", "response", "rurality", "satisfaction", "screening", "service delivery", "service intervention", "skills", "social media", "telehealth", "tool", "trait" ], "approved": true } }, { "type": "Grant", "id": "12232", "attributes": { "award_id": "1R35GM151145-01", "title": "Large-scale phylodynamics under non-neutral and non-treelike models of evolution", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Institute of General Medical Sciences (NIGMS)" ], "program_reference_codes": [], "program_officials": [ { "id": 24539, "first_name": "Ronald", "last_name": "Adkins", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2023-08-01", "end_date": "2028-05-31", "award_amount": 374491, "principal_investigator": { "id": 28104, "first_name": "Jonathan G", "last_name": "Terhorst", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [], "awardee_organization": { "id": 770, "ror": "", "name": "UNIVERSITY OF MICHIGAN AT ANN ARBOR", "address": "", "city": "", "state": "MI", "zip": "", "country": "United States", "approved": true }, "abstract": "Technological breakthroughs such as next-generation sequencing have recently led to the creation of immense “BioBanks” featuring genomic information collected from hundreds of thousands of people, and the ongoing pandemic has resulted in an even more extreme repository containing over 10 million SARS-CoV-2 genomes. Unfortunately, existing techniques for inferring evolutionary models can, in most cases, only analyze a tiny fraction of the information contained in these datasets. At a time when we should be able to use vast quantities of data to answer increasingly nuanced evolutionary questions, lack of adequate methods has limited our opportunities for discovery and hampered our ability to respond to the ongoing pandemic. The proposed research addresses this problem through the creation of novel statistical and computational methods designed to study targeted evolutionary hypotheses using BioBank- and pandemic-scale datasets. First, we will develop new phylodynamic methods for epidemiological inference using tens of thousands of sampled pathogen genomes. Apart from being more scalable, these methods will innovate over previous work by being more biologically realistic and making fewer simplifying assumptions about the data. In particular, we will study systems where multiple strains co-circulate and have differential fitness, and we will use this model to improve our understanding of the role that natural selection has played in shaping the pandemic. We will further extend this method to integrate non-genetic sources of information such as case count data, which will enable public health researchers to partition case counts into different variants and estimate variant-specific effective reproduction numbers. Second, we will develop improved methods for inferring phylogenetic networks, and use them to understand the role that recombination has played in the evolution of the coronavirus, as well as its role in confounding earlier studies that incorrectly assumed that SARS-CoV-2 evolution could be represented by a single tree. All of these advances will be implemented and released as easy to use open source software packages. In summary, this work represents advances in several areas of statistical genetics including phylodynamic modeling, genetic epidemiology, inference of natural selection and phylogenetic network analysis, and will provide empirical researchers with modern tools needed to propel the next generation of discoveries in these fields.", "keywords": [ "2019-nCoV", "Address", "Area", "Computer software", "Computing Methodologies", "Coronavirus", "Data", "Data Set", "Epidemiologic Methods", "Evolution", "Genetic", "Genetic Recombination", "Genome", "Genomics", "Learning", "Methods", "Modeling", "Modernization", "Natural Selections", "Pathway Analysis", "Persons", "Phylogenetic Analysis", "Play", "Public Health", "Reproduction", "Research", "Research Personnel", "Role", "SARS-CoV-2 genome", "Sampling", "Shapes", "Source", "Statistical Methods", "System", "Techniques", "Technology", "Time", "Trees", "Variant", "Work", "biobank", "combat", "design", "fitness", "genetic epidemiology", "improved", "innovation", "next generation", "next generation sequencing", "non-genetic", "novel", "open source", "pandemic disease", "pathogen genome", "repository", "tool" ], "approved": true } }, { "type": "Grant", "id": "12233", "attributes": { "award_id": "1R16GM149432-01", "title": "Impacts of Social Determinants of Health and COVID-19 Pandemic Factors on Suicide Risk among Youth", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Institute of General Medical Sciences (NIGMS)" ], "program_reference_codes": [], "program_officials": [ { "id": 23750, "first_name": "Irina N", "last_name": "Krasnova", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2023-08-01", "end_date": "2027-07-31", "award_amount": 136367, "principal_investigator": { "id": 28105, "first_name": "MARTIE P", "last_name": "Thompson", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [], "awardee_organization": { "id": 426, "ror": "https://ror.org/051m4vc48", "name": "Appalachian State University", "address": "", "city": "", "state": "NC", "zip": "", "country": "United States", "approved": true }, "abstract": "Suicide is a significant public health problem among youth. Data indicate suicidal behaviors were increasing among youth even before the COVID-19 pandemic began and have likely increased even more since its onset. This R16 proposed research seeks to address the urgent mental health crisis and respond to the recent advisories from the US Surgeon General that highlight the need for a better understanding of the impact of the pandemic on youth. We will meet this objective by pursuing the following specific aims: (1) Identifying the trajectory of suicide risk among youth across the pandemic period and testing if there have been differential changes based on demographics; (2) Determining how social determinants of health are related to suicide risk among youth; and (3) Characterizing the moderating and mediating roles of social determinants of health in the association between COVID-19 burden and suicide risk among youth. This research is innovative in several ways. First, it will apply a Social Determinants of Health framework and thus will widen the investigation of suicidal behavior risk factors beyond individual-level factors to include relevant social, economic, education, physical infrastructure, and healthcare risk factors, which have often been overlooked in COVID-19 mental health research with youth. Second, it will use real-time crisis response data to determine how suicide risk has changed over the course of the pandemic, an important asset given the reporting time lag involved with other data sources. Third, it will link data from large national databases (SDOH, Crisis Text Line, USAFacts) that each provides important and unique strengths (e.g., national, real-time, explores sexual orientation and race identity) to assess the direct, indirect, and interactive effects of social determinants of health and COVID-19 burden on suicidal behavior among youth. Our research team is particularly poised to undertake this investigation. The PI has extensive experience in suicide research, secondary data analysis, and mentoring students, and the Co-Investigators have experience using several of the proposed data sources and similar data analytic approaches as proposed. Further, Appalachian State University is an ideal institution to receive this award because Pell grants support 28% of its undergraduate students, it awards degrees in biomedical sciences, and has received only one NIH grant in the past two years.", "keywords": [ "Accident and Emergency department", "Address", "Age", "Appalachian Region", "Award", "COVID-19", "COVID-19 impact", "COVID-19 pandemic", "Cause of Death", "Communities", "Data", "Data Analyses", "Data Analytics", "Data Set", "Data Sources", "Databases", "Economics", "Education", "Environment", "Gender", "Grant", "Growth", "Health", "Healthcare", "Human Resources", "Individual", "Infrastructure", "Institution", "Investigation", "Lead", "Light", "Link", "Location", "Mediating", "Mental Health", "Modeling", "Persons", "Principal Component Analysis", "Public Health", "Publications", "Race", "Reporting", "Research", "Research Personnel", "Research Training", "Risk Factors", "Role", "Rural", "Rural Appalachia", "Science", "Sex Orientation", "Students", "Suicide", "Surgeon", "System", "Testing", "Text", "Time", "Training", "United States National Institutes of Health", "Universities", "Youth", "demographics", "digital mental health", "experience", "graduate student", "health disparity", "innovation", "multilevel analysis", "novel", "pandemic disease", "pandemic impact", "racial identity", "response", "sexual identity", "social", "social health determinants", "sociodemographic group", "student mentoring", "suicidal behavior", "suicidal risk", "suicide rate", "traumatic event", "undergraduate student" ], "approved": true } }, { "type": "Grant", "id": "12234", "attributes": { "award_id": "1R01AG083173-01", "title": "The Paycheck Protection Program and its Effects on Staffing Patterns and the Outcomes of Residents Living with Dementia", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Institute on Aging (NIA)" ], "program_reference_codes": [], "program_officials": [ { "id": 7229, "first_name": "Elena", "last_name": "Fazio", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2023-08-15", "end_date": "2028-04-30", "award_amount": 740150, "principal_investigator": { "id": 28106, "first_name": "Jason Raymond", "last_name": "Falvey", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [ { "id": 28107, "first_name": "Jasmine", "last_name": "Travers", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "awardee_organization": { "id": 167, "ror": "https://ror.org/0190ak572", "name": "New York University", "address": "", "city": "", "state": "NY", "zip": "", "country": "United States", "approved": true }, "abstract": ". Nursing home staff shortages are well known to be an important factor impacting both the quality of care that nursing home residents receive, their health outcomes, and healthcare worker outcomes. Staffing shortages are compounded by limited financial resources in nursing homes, especially for smaller nursing homes, which was further exacerbated by the COVID-19 pandemic. These staffing shortages disproportionately impact nursing home residents living with Alzheimer’s disease and related dementias (ADRD) as they require more time from staff compared to care for residents who do not have ADRD. As the number of Americans living with ADRD increases, the need for fully staffed nursing homes that can provide quality care for older adults living with ADRD is now more important than ever. During public health emergencies, direct funding to nursing homes has been proposed as an expedient way to prevent staffing losses and maintain safety standards for residents. One federal policy mechanism utilized by nursing homes during the COVID-19 pandemic was the Paycheck Protection Program (PPP). The PPP loan program offers a unique natural experiment by which to evaluate the effectiveness and efficacy of a program that directly funds small businesses and in the case of this project, nursing homes, to maintain safe staffing levels during public health emergencies. While PPP loans were effective overall at keeping workers on the payroll across all US small businesses, it is unclear if the effects of the program were equitable across nursing homes in socioeconomically deprived neighborhoods which prior work from our team showed have lower staffing rates. Using robust econometric methods and an exploratory sequential mixed methods approach, the proposed project will assess the effectiveness and equity of PPP funding by 1) examining changes in staffing patterns and resident outcomes among nursing homes that received the PPP loans compared to nursing homes that did not and evaluating whether changes in staffing patterns and outcomes were equitable for those with ADRD living in the most socioeconomically deprived facilities; 2) qualitatively exploring facility strategies, tools, and social contexts that promoted resilience to declines in staffing and ADRD resident outcomes after receipt of PPP, and 3) quantitatively assessing the extent to which resilience strategies, cultures, and behaviors identified in Aim 2 are reflected in administrative actions about staffing and care for residents with ADRD, and how actions differed by neighborhood context. The overall goal is to develop a framework by which to guide future nursing home responses to public health emergencies that will improve staff patterns and subsequent ADRD outcomes in the most socioeconomically deprived/lowest-resourced neighborhoods.", "keywords": [ "Address", "Alzheimer&apos", "s disease related dementia", "American", "Area", "Behavior", "Businesses", "COVID-19", "COVID-19 pandemic", "Caring", "Characteristics", "Clinical", "Data", "Dementia", "Development", "Diagnosis", "Disasters", "Disparity population", "Economic Factors", "Economics", "Effectiveness", "Elderly", "Eligibility Determination", "Emergency Situation", "Equity", "Event", "Excess Mortality", "Funding", "Future", "Goals", "Health", "Health Personnel", "Health Services Research", "Health care facility", "Home Nursing Care", "Hour", "Individual", "Infrastructure", "Intervention", "Interview", "Leadership", "Medicare", "Methods", "Natural experiment", "Neighborhoods", "Nurse Administrator", "Nursing Homes", "Nursing Staff", "Outcome", "Pattern", "Phase", "Policies", "Population", "Preparation", "Public Health", "Qualitative Research", "Quality of Care", "Reporting", "Resources", "Safety", "Shock", "Social Environment", "Structure", "Survey Methodology", "Surveys", "Time", "Work", "cohort", "community-level factor", "deprivation", "design", "econometrics", "economic disparity", "effectiveness evaluation", "experience", "federal policy", "health disparity", "improved", "improved outcome", "indexing", "mortality", "nursing care quality", "pandemic disease", "prevent", "programs", "promote resilience", "public health emergency", "resilience", "resilience factor", "response", "socioeconomics", "telehealth", "tool", "ventilation" ], "approved": true } }, { "type": "Grant", "id": "12235", "attributes": { "award_id": "1R13AI179176-01", "title": "11th Annual Meeting of International Cytokine & Interferon Society", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Institute of Allergy and Infectious Diseases (NIAID)" ], "program_reference_codes": [], "program_officials": [ { "id": 23719, "first_name": "Susan F.", "last_name": "Cooper", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2023-08-15", "end_date": "2024-07-31", "award_amount": 5000, "principal_investigator": { "id": 28108, "first_name": "James K", "last_name": "Turkson", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [], "awardee_organization": { "id": 766, "ror": "https://ror.org/02pammg90", "name": "Cedars-Sinai Medical Center", "address": "", "city": "", "state": "CA", "zip": "", "country": "United States", "approved": true }, "abstract": "The purpose of this application is to request financial support for Cytokines 2023: 11th Annual Meeting of the International Cytokine & Interferon Society (ICIS), October,15-18, 2023, with llivestream and on-demand virtual access through October 29, 2023. This Annual Meeting helps bridge the gap between the scientists performing basic research on molecular and cellular mechanisms of immune cell activation and function with those working to develop this knowledge into novel therapies. The 11th edition comes at a time when cytokine biology, cytokine biomarkers and cytokine therapeutics are revolutionizing modern medicine, providing novel treatments for a wide variety of diseases ranging from lethal inflammatory, autoimmune and allergic diseases, to viral infections and cancer. This year’s theme is “Cytokines and interferons in the precision medicine era”, focusing on the latest developments on cytokine biology in relation to immune regulation, host damage and disease, and the latest progress on cytokines/cytokine inhibitors as novel therapeutics in the clinic. A variety of topics will be covered by leaders in the field in the plenary and parallel sessions such as innate immunity and host defense, adaptive immunity, cytokines in T and B cell responses to vaccination, in Long COVID, HIV and novel targeted therapies from cancer immunotherapy to novel therapeutics in autoimmunity. Since a major goal of the meeting is to promote interactions between scientists and clinicians working in basic, translational or applied research, ample opportunity will be given to poster networking sessions to present the latest advances elated to cytokine research, biomarkers and therapeutics. Greater understanding of mechanisms of disease and novel concepts for therapy have and will continue to emerge from interdisciplinary gatherings where advances can be presented and discussed by established and trainee scientists. The meeting will focus on cytokines in personalized medicine and will provide an opportunity for updates on the development of novel therapeutic interventions in these fields and help spur international collaborations among the meeting participants. Although meeting participants will have primary interests in infectious diseases, cancer and immune-mediated diseases, the program integrates speakers on the periphery of Cytokine and Interferon research to help bridge these disciplines. This interdisciplinary environment is particularly interesting for early career researchers who are not only focused on their own field of research but are beginning to think about the wider implications of their work. Our goal is to increase attendance of early career investigators and trainees and also to achieve higher representation of underrepresented minorities at all levels of career development. Online presentations will consist of livestreamed video presentations for all speakers who give their permission to be recorded, to benefit virtual attendees as well as in-person attendees to access content from parallel sessions or missed presentations. ICIS Meetings Committee and Council have decided that included virtual access even without travel restrictions, makes the Annual Meeting more inclusive and sustainable.", "keywords": [ "Allergic Disease", "Amaze", "Applications Grants", "Applied Research", "Arthritis", "Authorization documentation", "Autoimmune Diseases", "Autoimmunity", "Award", "B-Lymphocytes", "Basic Science", "Biological Markers", "Biology", "Biotechnology", "Budgets", "COVID-19", "COVID-19 impact", "Chronic Disease", "Clinic", "Clinical Research", "Collaborations", "Communicable Diseases", "Country", "Cytokine Network Pathway", "Data", "Development", "Diabetes Mellitus", "Discipline", "Disease", "Event", "Feedback", "Financial Support", "Future", "Goals", "Government", "Greece", "HIV", "Hawaii", "Health", "Host Defense", "Human", "Hybrids", "Immune", "Infection", "Inflammation", "Inflammatory", "Institution", "Interferons", "International", "Intuition", "Kidney Diseases", "Knowledge", "Lightning", "Lobbying", "Long COVID", "Love", "Malignant Neoplasms", "Mediating", "Modern Medicine", "Molecular", "Natural Immunity", "Parents", "Participant", "Persons", "Pharmacologic Substance", "Proteins", "Qualifying", "Reporting", "Research", "Research Personnel", "Rheumatoid Arthritis", "Role", "Scientist", "Societies", "Students", "T-Lymphocyte", "Therapeutic", "Time", "Translational Research", "Travel", "Underrepresented Minority", "Update", "Vaccination", "Viral Cancer", "Virus Diseases", "Work", "adaptive immunity", "cancer immunotherapy", "career", "career development", "collaborative environment", "cost", "cytokine", "design", "digital platform", "exhibitions", "flexibility", "fundamental research", "immune activation", "immunoregulation", "inhibitor", "interest", "live stream", "meetings", "multidisciplinary", "new therapeutic target", "novel", "novel therapeutic intervention", "novel therapeutics", "personalized medicine", "posters", "precision medicine", "programs", "response", "symposium", "targeted cancer therapy", "therapeutic target", "virtual", "virtual platform" ], "approved": true } } ], "meta": { "pagination": { "page": 1392, "pages": 1392, "count": 13920 } } }